Understanding how malignancies arise within normal tissues requires identification of the cancer cell of origin and knowledge of the cellular and tissue dynamics of tumour progression. Here we examine bladder cancer in a chemical carcinogenesis model that mimics muscle-invasive human bladder cancer. With no prior bias regarding genetic pathways or cell types, we prospectively mark or ablate cells to show that muscle-invasive bladder carcinomas arise exclusively from Sonic hedgehog (Shh)-expressing stem cells in basal urothelium. These carcinomas arise clonally from a single cell whose progeny aggressively colonize a major portion of the urothelium to generate a lesion with histological features identical to human carcinoma in situ. Shh-expressing basal cells within this precursor lesion become tumour-initiating cells, although Shh expression is lost in subsequent carcinomas. We thus find that invasive carcinoma is initiated from basal urothelial stem cells but that tumour cell phenotype can diverge significantly from that of the cancer cell of origin.
The idea that human malignancies may originate from adult tissue stem cells derives from the intrinsic ability of stem cells to self-renew, from their longevity and consequent ability to accrue multiple mutations, and from the phenotypic resemblance of tumourpropagating cells to tissue stem cells [1] [2] [3] [4] . Experimental tests of this hypothesis, however, have revealed a surprising degree of complexity 5 . Recent mouse studies using cell-specific genetic manipulation have produced evidence that ovarian cancer, glioblastoma, skin cancer and intestinal adenomas/carcinomas are derived from tissue stem cells [6] [7] [8] [9] [10] , but other studies have suggested that luminal epithelial cells may serve as the cancer cell of origin. Thus, in mouse mammary tissue, tumours of greatest histological similarity to human mammary adenocarcinoma arise on Cre-mediated deletion of Brca1/Tp53 in luminal cells, even though aggressive human mammary tumours are phenotypically basal in character 11, 12 . Similarly, with oncogene expression and transplantation into the murine kidney capsule as an assay, prostate adenocarcinoma arises exclusively from basal cells of mouse 13, 14 or human 15 prostate whereas autochthonous adenocarcinomas caused by deletion of PTEN can arise from either basal or luminal cells 16, 17 , and the more aggressive cancers arise from luminal cells. Several haematopoietic malignancies seem to arise not from stem but from progenitor cells, even when essential precursor genetic lesions are also present in the stem cells 18 . Finally, it is worth noting that many of these studies involve manipulation of a selected set of genetic pathways in a subset of cells of the target organ, which might reveal only a limited subset of the possible paths along which a malignancy may develop.
Carcinoma of the urinary bladder arises from the urothelium, a simple transitional epithelium lining the bladder lumen. This multilayered epithelium consists of a luminal layer of fully differentiated umbrella cells that overlie intermediate cells with limited proliferative potential, and a basal layer of Shh-expressing cells. The Shh-expressing cells can form and propagate bladder-like organoids from single cells in vitro, and when genetically marked in vivo can be shown to replenish all other urothelial cells following injury, a regenerative activity that persists through multiple rounds of injury over long periods of time 19 . These properties identify Shh-expressing basal cells as probable urothelial stem cells.
The pro-carcinogen N -butyl-N -4-hydroxybutyl nitrosamine (BBN) is specifically activated in bladder and induces aggressive muscle-invasive bladder carcinoma over time with little effect on other tissues 20, 21 . Nitrosamines are potent mutagens present in cigarette smoke 22 , which is the most important known risk factor for human bladder cancer 23, 24 . Here, using BBN carcinogenesis and genetic tools to mark or ablate cells, we demonstrate that Shh-expressing basal stem cells of the urothelium are the cell of origin for murine invasive urothelial carcinoma. Using multi-colour cell marking and lineage tracing, we also show that precursor lesions during progression to invasive carcinoma arise from aggressive clonal expansion of single urothelial cells whose progeny colonize a major portion of the urothelium to generate a carcinoma in situ (CIS) precursor lesion. Finally, although Shh-expressing cells within this lesion become tumour-initiating cells, Shh expression is lost by the time carcinomas develop, demonstrating that the phenotypic properties of mature tumour cells can diverge from those of the cancer cell of origin.
RESULTS

Similarity of human and BBN-induced mouse bladder cancer
We examined mouse bladder tissues after exposure to BBN in drinking water and noted that the histopathology of BBN-exposed bladders in our murine model evolves in a manner similar to human muscleinvasive carcinoma 21, 25 . Bladder tissues thus appear normal, without cellular changes or tissue disorganization within the first 2 months of BBN exposure ( Fig. 1a and Supplementary Table 1 ). Histologic abnormalities appeared at 3 months of BBN exposure, including areas of nuclear atypia, crowding, and architectural disarray histologically indistinguishable from human CIS ( Fig. 1b and Supplementary  Table 1 ). At 4 months of BBN exposure, CIS became robust and widespread in most animals, with extensive urothelial thickening ( Fig. 1b and Supplementary Table 1 ), and muscle-invasive carcinoma invariably developed by 6 months of BBN exposure ( Fig. 1b and Supplementary Fig. 1 ), with consequent illness and morbidity necessitating euthanasia by 8 months of BBN exposure. The urothelial thickening caused by BBN exposure is distinct from hyperplasia that is rapidly induced by bacterial or chemical injury 19 , as it requires months of BBN exposure to arise, does not recede, and is associated with CIS ( Supplementary Fig. 2 ).
CIS and invasive carcinoma develop from Shh-expressing basal stem cells
The presence of basal cell character in tumour-propagating cells 26, 27 is consistent with our observation that the basal cell marker CK5 is expressed throughout BBN-induced tumours (see below). As other cancers with basal character derive from luminal cells 11, 12 , we examined the cancer cell of origin by prospective marking of basal urothelial stem cells. We injected Shh CreER ; R26 mTmG mice with tamoxifen (TM) to activate CreER and induce excision of mT (membrane-targeted tdTomato) and permanent marking of Shh-expressing basal cells and their progeny by expression of mG (membrane-targeted enhanced green fluorescent protein (EGFP)). TM treatment was followed by 4-and 6-month courses of exposure to BBN ( Fig. 2 and Supplementary Fig. 3 ). We noted mG marking of both the CIS lesion at 4 months (5/5 mice) and invasive carcinomas at 6 months (6/6 mice; Fig. 2a,b and Supplementary Fig. 3a ,b), indicating that both derive from Shh-expressing basal stem cells and that CIS may represent a precursor lesion in muscle-invasive carcinoma development, as widely believed in human patients 25 . Importantly, no unmarked invasive carcinomas were observed, despite the presence of many unmarked supra-basal and luminal cells at the beginning of BBN exposure, suggesting that invasive carcinoma is exclusively derived from Shh-expressing basal stem cells.
Ablation of basal stem cells abrogates BBN carcinogenesis
We explicitly tested the requirement for basal stem cells in tumour formation by injecting TM into mice of the genotype Shh CreER ; R26 DTA , in which expression of an attenuated form of the diphtheria toxin fragment A (DTA; refs 28-30) results in highly efficient ablation of Shh-expressing basal cells and consequent loss of high levels of CK5 expression. The low levels of CK5 in remaining cells resemble those normally seen in intermediate cells ( Fig. 3a) , which do not express Shh.
These mice failed to maintain normal bladder epithelial architecture ( Fig. 3b ) and died within 8-10 months, consistent with previous findings on urothelial turnover 31 and the role of basal urothelial stem cells in bladder homeostasis 19 .
On exposure to BBN we found that vehicle-injected control mice developed invasive carcinoma marked by high-level expression of CK5 (7 of 7 mice, Fig. 3c and Supplementary Fig. 4 ), whereas TM-injected mice, in which basal stem cells were ablated, did not develop invasive carcinoma (0 of 7 mice, Fig. 3c ), even when BBN exposure continued for 8 months ( Supplementary Fig. 4 ). Basal stem cells thus are absolutely required for formation of BBN-induced tumours, and the more differentiated supra-basal and luminal cells that remain in these TM-injected animals are not susceptible to BBNinduced carcinogenesis. The finding that BBN-induced carcinomas are comprised entirely of the progeny of marked basal stem cells without contribution from unmarked intermediate or luminal cells, together with the failure of BBN to induce tumours within animals lacking basal stem cells, constitutes strong evidence that invasive bladder carcinoma originates exclusively from the Shh-expressing basal urothelial stem cell.
Although TM-injected Shh CreER ; R26 DTA animals exposed to BBN for 6 months exhibited disrupted epithelial architecture ( Fig. 3c ), epithelial integrity was preserved after 3 or 4 months of BBN exposure, with only mild urothelial thickening (Fig. 3d ). The residual levels of CK5 expression were similar to those of normal intermediate urothelial cells (Fig. 3a ), suggesting that the limited urothelial thickening induced by BBN exposure may be supported by proliferation of intermediate cells. Progressive deterioration of urothelial integrity over longer periods of time in animals lacking basal stem cells, with or without carcinogen treatment, suggests the exhaustion of limited proliferative capacity of these intermediate cells.
To determine how loss of basal stem cells affects CIS during tumorigenesis of BBN-induced invasive cancer, histopathology of TM-injected Shh CreER ; R26 DTA animals was evaluated at monthly intervals during BBN exposure. These animals developed CIS lesions to a significantly reduced extent (Fig. 4a,b and Supplementary Tables 2  and 3 ). Epithelial architecture in basal cell-ablated bladders was maintained after 3 or 4 months of BBN exposure, with normal expression of the luminal marker CK18 ( Fig. 4c,d) . The low frequency of CIS and absence of tumours at later stages of BBN exposure ( Fig. 3c ) in these mice thus are not due to gross disruption of urothelial architecture, and these results together strongly suggest that Shh-expressing basal cells are a cell of origin for invasive carcinomas and for precursor lesions during bladder tumorigenesis.
Shh-positive cells in the intermediate lesion as a cell of origin of tumour-propagating cells
To analyse the expression of Shh during tumour progression, Shh CreER ; R26 mTmG mice were exposed to BBN for 4 months to generate CIS lesions, then injected with TM to label Shh-expressing cells a few days before euthanization ( Fig. 5a , upper left). We found that although all cells in CIS lesions of these mice expressed CK5 at a high level ( Fig. 5a and Supplementary Fig. 5a ), only a basal subset of these CK5-positive cells expressed mG, indicating maintenance of Shh expression in a basal subpopulation of CK5-positive cells ( Fig. 5a and Supplementary  Fig. 5a ). Other more luminal progeny of these basal cells lack Shh expression but retain high levels of CK5.
To investigate the cancer-forming capacities of these two CIS cell populations, Shh CreER ; R26 mTmG mice previously exposed to BBN for 4 months were injected with TM, thus marking Shh-positive cells in the basal layer, whereas the remaining cells retain expression of mT. These mice were then subjected to further exposure to BBN for 2 months (Fig. 5b ). These mice developed aggressive bladder cancers ( Fig. 5c Figure 3 Ablation of Shh-expressing basal stem cells confers resistance to nitrosamine-induced formation of invasive bladder carcinoma. (a) TM was injected into Shh CreER ; R26 DTA mice on 5 consecutive days. Five days after the last TM injection, bladders were analysed by immunostaining. Sections from the bladders of control vehicle-injected or TM-injected mice (left and right panels, respectively) were stained for CK5 (green). Note that TM treatment effectively ablates basal epithelial cells in the Shh CreER ; R26 DTA mouse bladder. (b) Shh CreER ; R26 DTA mice were injected with TM on 5 consecutive days to ablate Shh-expressing basal cells and were maintained for 8 months without BBN exposure. Histology of the bladder from a mouse 8 months after TM injection shows the failure of maintenance of normal bladder epithelium, resulting from loss of stem cells. The right panel shows an enlarged view of the outlined region in the left panel. (c,d) TM was injected into Shh CreER ; R26 DTA mice on 5 consecutive days to ablate Shh-expressing basal cells, and mice were exposed to BBN for 6 (c) or 4 (d) months. Bladder tissues were analysed by H&E staining (left panels) and immunostaining for CK5 (green, right panels). The upper panels show bladders from vehicle controls (no TM). L, bladder lumen. Repeated experimental results for c are shown in Supplementary Fig. 4 . Scale bars, 50 µm.
We established transplant models in which cells from primary BBN-induced bladder tumours were injected into immunocompromised mice to give rise to a secondary tumour, either orthotopically into the intramural portion of the bladder dome (Supplementary Fig. 5c ) or subcutaneously into the flank. We then used these transplant models to test genetically marked cells from Shh CreER ; R26 mTmG animals treated with TM at 4 months, followed by exposure to BBN for an additional 2 months as described above (Fig. 5b ). EpCAM + cells (expressed in tumour cells, not in stroma) marked by expression of mG + or mT + were separated by fluorescence-activated cell sorting (FACS; Supplementary Fig. 5b ) and transplanted orthotopically at three dilutions to test their tumour-propagating abilities ( Fig. 5d ). We found that mG + cancer cells at all three dilutions were able to give rise to secondary tumours, whereas mT + cells did not ( Fig. 5e and Supplementary Fig. 5d ). Similar results were noted when cancer cells were separated by using only mG or mT expression in the subcutaneous model ( Supplementary Fig. 6 ). We conclude that Shh-expressing cells in the CIS lesions generate (Supplementary Tables 2 and 3 ). Scores from 0 to 3 are based on the extent of CIS within urothelium (0, none; 1, <10%; 2, 10-30%; 3, >30%). No invasive carcinoma and little or no CIS was induced by BBN exposure in animals with ablated stem cells. n = 4 (1 month), n = 4 (2 months), n = 8 (3 months), n = 8 (4 months) for vehicle-treated Shh CreER ; R26 DTA mice; n = 4 (1 month), n = 4 (2 months), n = 8 (3 months), n = 9 (4 months) for TM-treated Shh CreER ; R26 DTA mice. Data are presented as mean ± s.e.m. (c,d) Shh CreER ; R26 DTA mice were injected with TM on 5 consecutive days to ablate Shh-expressing basal cells and exposed to BBN for 3 (c) and 4 (d) months. Sections from the bladders of control vehicle-injected or TM-injected mice (top and bottom panels, respectively) were stained for the luminal and basal markers, CK18 and CK5 (green and red, respectively). Note that luminal cells are well preserved at intermediate stages of BBN exposure in stem-cell-ablated animals. L, bladder lumen. Scale bars, 50 µm.
the carcinoma cells that are capable of propagating the tumour in transplantation experiments.
Absence of Shh expression in invasive carcinoma
In our BBN murine model invasive carcinomas arise from Shhexpressing basal stem cells, with tumour development progressing through basal cells of the intermediate CIS lesion. As previous analyses revealed very low or undetectable expression of SHH messenger RNA in a group of human bladder carcinoma samples 32 , we further investigated Shh expression by inducing invasive carcinomas with 6 months of BBN exposure in Shh CreER ; R26 mTmG mice, then injecting with TM a few days before euthanization ( Fig. 6a ). We found that invasive carcinomas were entirely devoid of mG ( Fig. 6b) , which should provide a reliable indication of Shh expression 19 , despite continued strong expression of CK5. We further confirmed that expression of Shh is lost on progression to invasive carcinoma by quantitative PCR with reverse transcription from material obtained by laser capture microdissection from BBN-induced bladder tumours (Fig. 6c,d and Supplementary Fig. 7 ). Thus, although Shh expression marks the basal cell of origin for invasive carcinomas and persists in the precursor lesion for these tumours, it is completely absent in the fully formed tumour. Our results with BBN-induced invasive bladder carcinoma mirror those reported for a set of human transitional cell carcinoma samples 32 , most of which were invasive 33 .
Lineage and clonality in BBN-induced bladder carcinoma
The development of recurrent, multifocal tumours is a common characteristic of human urothelial carcinoma, with some studies concluding that such tumours are clonally related, whereas others argue for distinct cellular origins [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . To investigate lineage R26 mTmG mice exposed to BBN for 4 months and injected with TM on 3 consecutive days were subsequently exposed to BBN for 2 more months. Invasive carcinomas from these animals were analysed by H&E staining (left panel) or for expression of mG or mT, which respectively marks cells that expressed (green) or did not express (red) Shh at the time of TM injection. Supplementary Fig. 5a,d , respectively. Scale bars, 50 µm.
relationships and tissue dynamics in our model we used multicolour marking before BBN-induced carcinogenesis. The 'Rainbow' mouse [44] [45] [46] (R26 Rainbow ; Fig. 7a ) initially expresses EGFP but can recombine in a Cre-dependent fashion to express any of three additional distinct fluorescent proteins. Individual cells in the bladders of Actin CreER ; R26 Rainbow mice treated with an appropriate level of TM thus are stochastically labelled in approximately equal numbers by permanent and heritable expression of one of four distinct fluorescent proteins (Fig. 7a,b and Supplementary Fig. 8 Figure 6 Shh expression is lost in invasive carcinoma of murine bladder. (a) Experimental scheme for marking of Shh-expressing cells in invasive carcinoma induced by 6 months of BBN exposure. (b) Shh CreER ; R26 mTmG mice exposed to BBN for 6 months were injected with TM on 3 consecutive days to label Shh-expressing cells before euthanization, and the bladder carcinoma was analysed by H&E staining (left panel) or by immunostaining for mG and CK5 (green and red, respectively, in middle and right panels), with DAPI staining to visualize nuclei. Note the lack of mG expression in the carcinoma, indicating the absence of Shh expression, whereas CK5 expression is seen in all cancer cells. (c) Laser capture microdissection (LCM) of normal basal cell layer (upper panels) in untreated bladder and of carcinoma cells within tumour (lower panels). Nine tumour areas were assessed (3 different tumour areas from 3 distinct tumours) and representative images are shown here (area no. 1 from tumour no. 1). Other areas from 3 distinct tumours (area nos 2-3 in tumour no. 1; area nos 1-3 for tumour no. 2; area nos 1-3 from tumour no. 3) are shown in Supplementary Fig. 7a. (d) Shh mRNA is detected in cells microdissected from normal basal cells but absent from carcinoma cells. ND, not detected. Data are presented as mean ± s.e.m. from 3 technical replicates; 9 tumour areas were assessed (3 different tumour areas from 3 distinct tumours). Scale bars, 50 µm. and spanning extensive regions of contiguous cells (Fig. 7c , CIS no. 1). The entire urothelium thus consists of the progeny of one (monoclonal) or at most a few cells (oligoclonal; Fig. 7c , CIS no. 2).
On further BBN exposure we observed that invasive carcinomas seem to arise clonally, with a large tumour of a single colour occupying the entire bladder (monoclonal; Fig. 7d ) or with a few discrete tumour foci that are each labelled with a single colour (oligoclonal; Fig. 7e ). Oligoclonal tumours are usually accompanied by nearby CIS regions of the same colour ( Fig. 7e ) and such clonally related CIS regions can be easily identified when the tumour is less advanced. Thus, at 5 months of BBN exposure we observed two distinctly marked CIS lesions together occupying the entire urothelium, with a small carcinoma beginning to develop entirely within one of these two distinctly marked CIS lesions (Fig. 7c , CIS no. 2). Taken together, our observations suggest that CIS lesions develop clonally from one or a few cells with the remarkable ability to aggressively spread and displace other urothelial cells within major contiguous portions of the urothelium.
DISCUSSION
Nitrosamines are powerful mutagens found in cigarette smoke, which is the most important known risk factor for human bladder cancer [22] [23] [24] . Our use of the bladder-specific carcinogen BBN in the mouse thus mimics human bladder carcinogenesis in the type of carcinogen employed, in the lack of any prior bias regarding cell type or genetic pathway, and in carcinogen exposure over an extended period of time, thus permitting incremental progression and cell selection through genetic and tissue changes.
The previous identification of Shh-expressing basal cells as urothelial stem cells was based in part on in vivo genetic marking 19 . Our use in this work of chemical carcinogenesis rather than genetic methods to induce urothelial carcinoma was a critical factor in permitting use of the same genetic methods to mark Shh-expressing basal stem cells and show that they give rise to invasive urothelial carcinomas. Our findings exclude other urothelial cells as the cell of origin because marking of Shh-expressing basal cells exclusively generates marked tumours and because ablation of these cells renders the bladder incapable of generating a tumour. Although it is conceivable that tumours from supra-basal cells could be marked if basal cells generate other urothelial cell types during BBN exposure, we should also then see some unmarked tumours, as many unmarked supra-basal cells are also present in the urothelium at the time of BBN exposure. Furthermore, conversion of basal cells to supra-basal cells is a low-frequency event, as we see very little proliferation and urothelial turnover within the first months of BBN exposure ( Supplementary Fig. 2) . Similarly, if tumours could arise from suprabasal cells, we would expect to see tumours arising in the experiment that ablates Shh-expressing cells, as the urothelium appears normal with respect to its basic architecture and retains intermediate cells and well-differentiated umbrella cells. The fundamental integrity of the urothelium in these animals is suggested by their survival for at least 8 months after the ablation of stem cells, and is consistent with the previous assessment of a 10-month turnover time for murine urothelium 31 . The exclusive presence of marked tumours in the marking experiment and the absence of tumours in the ablation experiment together constitute strong positive and negative evidence that clearly identifies the Shh-expressing basal urothelial stem cell as the exclusive cell of origin in invasive bladder carcinoma.
As recently demonstrated, tumour-propagating cells isolated from human bladder carcinomas have basal character 26, 27 , and thus resemble the basal cell of origin identified here. This relationship, however, is distinct from that in tumours such as mammary adenocarcinoma, in which a tumour with basal character arises from a luminal cell of origin 11, 12 , or prostate adenocarcinoma, which has luminal character but evidently can originate from luminal or basal cells [13] [14] [15] [16] [17] . In addition, despite the apparent basal character of tumour-propagating cells of bladder carcinoma, most human invasive bladder carcinomas and the invasive carcinoma cells of our murine model differ strikingly from their cells of origin in having lost expression of Shh.
In human bladder carcinogenesis, CIS is widely thought of as a precursor to invasive carcinoma 25 . Such lesions have long been thought of as stages in the development of other cancers, as well. For example, prostatic intraepithelial neoplasia in prostate adenocarcinoma 47, 48 , pancreatic intraepithelial neoplasia in pancreatic adenocarcinoma 49, 50 , mammary ductal CIS (ref. 51) , and adenomatous polyps of the colon 52 are commonly discussed as intermediate stages of cancer progression, and these lesions often carry genetic alterations similar to those of fully developed carcinomas. Conclusive evidence tracing the origin of malignancy directly to such precursor lesions, however, has largely been lacking. The tools of lineage tracing applied here in the murine BBN model allow us to definitively address the relationship of intermediate lesions to invasive carcinoma, and we have been able to confirm not only that CIS is within the lineage leading to invasive carcinoma, but also to identify basal Shh-expressing cells within the CIS lesion as the cells that acquire tumour-propagating ability on formation of an invasive carcinoma.
One of the most striking findings to emerge from our multi-colour lineage studies in the BBN model is the remarkable ability of a single urothelial cell to sweep through and displace all other cells within a large contiguous portion of the urothelium. This finding is probably relevant to the extensive literature on clonal relationships among synchronous or metachronous human bladder tumours [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . The tools that previously have been used to determine clonal relationships include X-inactivation analysis, comparative genome hybridization, loss of heterozygosity analyses, and mutational analysis to compare chromosomal and genetic alterations in different tumours. The conclusions of these studies vary, and it has been proposed that multifocal tumours with a monoclonal origin may have divergent late genetic changes whose analysis could lead to the erroneous conclusion that they are multiclonal 53, 54 . The uncertainty in interpreting these types of results thus arises in part from uncertainty regarding the sequence of genetic events within tumours that are used as the basis for analysis. Our multi-colour marking experiments in the BBN model use distinctive marks generated before carcinogenesis and thus remove all ambiguity with regard to sequence. Our observation that a single marked cell under mutagenic pressure can aggressively proliferate and spread through extensive contiguous regions of the urothelium provides a clear basis for the clonal relationships identified among multifocal tumours within a single bladder [34] [35] [36] [37] [38] . This aggressive intraepithelial expansion of a single clone and our observations of invasive tumours surrounded by non-invasive regions of clonally related CIS urothelium also provide a correlate for the commonly reported occurrence of a tumour surrounded by a region of abnormal but benign epithelium [55] [56] [57] . Finally, the occurrence of two or three unrelated CIS lesions or tumours within a single bladder illustrates the possibility of generating multifocal tumours of distinct clonal origin; the probability of this occurrence may depend on the degree of mutagenic pressure.
The events of carcinoma initiation and progression are summarized in Fig. 8 , and begin with accumulation of mutations in Shh-expressing urothelial basal stem cells, the cancer cell of origin. These mutations allow the progeny of a single cell to sweep through and colonize an extensive portion of the urothelium and form a CIS precursor lesion. Within this lesion, Shh-positive basal cells accumulate further mutations, leading to further clonal expansion and ultimately to transformation and invasion of the stromal and muscle layers of the bladder. The latter stages of this process are consistently accompanied by loss or attenuation of Shh expression, and further studies will be required to establish the significance of this loss. One of the key features of our findings is that progression to invasion occurs in the context of a precursor lesion with pre-neoplastic changes that aggressively spreads through most if not all of the urothelium. Resection of invasive carcinomas, even if complete, thus may leave in place urothelial cells that already have taken several early steps along the path to invasive tumour formation, thus potentially accounting for the frequent recurrence and high morbidity of invasive human bladder cancer.
METHODS
Methods and any associated references are available in the online version of the paper. For lineage tracing experiments, Shh CreER/WT mice were mated with the R26 mTmG/mTmG strain to obtain Shh CreER/WT ; R26 mTmG/WT mice. For cell ablation experiments, Shh CreER/WT mice were mated with the R26 DTA/WT strain to obtain Shh CreER/WT ; R26 DTA/WT mice. For cancer clonality studies, TM-activated Cre combined with R26 Rainbow/WT was used to mark cells and their progeny with one of four fluorescence colours. All mouse strains except for Rainbow mice were obtained from Jackson Laboratories. Male mice at 8-10 weeks of age at the beginning of BBN treatment were used. For each experiment, no statistical method was used to predetermine sample size, and mice in each cage were randomly selected for drug/TM or control treatments. The investigators were blinded to allocation during experiments and outcome assessment. Histological assessment of bladder tissue sections was blinded to ensure that the pathologist who assessed the tissues did not know which treatment group each sample belonged to. Mouse procedures were performed under isoflurane anaesthesia, which was administered in a fume hood with a standard vaporizer (J.B. Baulch and Associates). All procedures were performed under a protocol approved by the Administrative Panel on Laboratory Animal Care at Stanford University.
BBN-induced bladder carcinogenesis.
A 0.1% concentration of BBN (TCI America) was dissolved in drinking water, and BBN-containing water was provided to mice ad libitum for 4-6 months in a dark bottle. BBN-containing water was changed twice a week. Bladders were collected and analysed after 4-6 months of BBN administration.
Lineage tracing studies. For lineage marking of Shh-expressing basal cells before BBN exposure, Shh CreER/WT ; R26 mTmG/WT mouse strains were injected intraperitoneally with 4 mg of TM per 30 g body weight daily for 3 consecutive days. BBN-containing water was provided to mice ad libitum for 4 or 6 months beginning 5 days after the last TM injection. Mice were euthanized and bladders dissected for further analysis. For marking and tracing of Shh-expressing hyperplastic cells, Shh CreER/WT ; R26 mTmG/WT mice were exposed to BBN for 4 months and then injected intraperitoneally with 4 mg of TM (per 30 g body weight) daily for 3 consecutive days. Mice were then provided with BBN-containing water for an additional 2 months, euthanized and bladders dissected for further analysis. To label Shh-expressing cells in invasive carcinoma, Shh CreER/WT ; R26 mTmG/WT mouse strains were provided with BBN-containing water for 6 months and then injected intraperitoneally with 4 mg of TM (per 30 g body weight) daily for 3 consecutive days. Mice were euthanized 5 days after the last TM injection, and bladders were analysed. To label Shh-expressing cells in CIS lesions, Shh CreER/WT ; R26 mTmG/WT mouse strains were provided with BBN-containing water for 4 months and then injected intraperitoneally with 4 mg of TM (per 30 g body weight) daily for 3 consecutive days before mice were euthanized. For cancer clonality studies, Actin CreER/WT ; R26 RAINBOW/WT mouse strains were injected with 2 mg of TM (per 30 g body weight) before BBN exposure. Note that owing to poor expression of Actin CreER , bladder stromal cells retain the original expression of EGFP.
Cell ablation studies. For ablation of Shh-expressing cells before BBN exposure, Shh CreER/WT ; R26 DTA/WT mice were injected intraperitoneally with 4 mg of TM (per 30 g body weight) daily for 5 consecutive days. Bladders then were examined for ablation of basal cells 5 days after the last TM injection. For studies on the effect of basal cell loss on bladder tumorigenesis, BBN-containing water was provided to mice ad libitum for 4-6 months after basal cell ablation by daily TM injection for 5 days as described above. Mice were then euthanized and bladders then dissected for further analysis.
Immunofluorescence analysis. Bladders were dissected and embedded in OCT compound for snap freezing (Tissue-Tek). Frozen blocks were sectioned at 10 mm intervals using a Microm cryostat. For immunostaining, frozen tissue sections were fixed in 4% paraformaldehyde for 30 min at 4 • C. After washing three times with PBS, tissue sections were blocked in 2% goat serum in PBS containing 0.25% Triton X-100 for 1 h, and incubated with primary antibodies diluted in blocking solution overnight at 4 • C in a humidified chamber (rabbit anti-CK5, 1:300 dilution, ab53121 from Abcam; rat anti-CK18/8, 1:300 dilution, Troma-I from hybridoma bank; rabbit anti-GFP, 1:1,000 dilution, A-11122 from Invitrogen). Sections were washed three times with PBS containing 0.25% Triton X-100, incubated with DAPI and appropriate Alexa fluor 488-, 594-or 633-conjugated secondary antibodies diluted 1:1,000 in blocking solution for 2 h at room temperature, washed again three times, and mounted on slides with Prolong Gold mounting reagent (Invitrogen). All images were obtained using a Zeiss LSM 510 inverted confocal microscope and prepared for publication with Zeiss LSM 5 Image Browser software and Adobe Photoshop CS3.
Laser capture microdissection. For laser capture microdissection (LCM), bladder sections were prepared using an LCM staining kit (Ambion) and a Leica LMD6000 Laser Microdissection Microscope. After LCM, total RNA was prepared using RNAqueous-Micro RNA isolation kit (Ambion). Quantitative PCR with reverse transcription was performed using iScript one-step RT-PCR kit with SYBR Green and the Bio-Rad iCycler (BioRad). All values were normalized to the HPRT internal control.
Tumour transplantation. Bladder tumours were minced, and then incubated with Liberase blendzymes 2 and 4 (Roche) in DMEM (Invitrogen) at 37 • C for 3 h. A single-cell suspension was obtained by 10 min of trituration every 30 min during this incubation, followed by filtration through 70 µm cell strainers. After the lysis of red blood cells, cells were washed with HBSS/2% fetal bovine serum and were counted using a haemocytometer (Hausser Scientific). Cells were resuspended in 100 µl HBSS containing 30% Matrigel (BD Bioscience) and then injected with 31-gauge insulin syringes (Becton Dickinson) subcutaneously into the flanks of anaesthetized NSG mice (Jackson Laboratories). For the transplantation of genetically labelled cells, Shh CreER/WT ; R26 mTmG/WT mice were exposed to BBN for 4 months and then injected intraperitoneally with 4 mg of TM per 30 g body weight daily for 3 consecutive days. Mice were provided with BBN-containing water for an additional 2 months. Bladder tumours from resulting mice were dissociated as described above. Cells were sorted using a FACS AriaII cytometer (BD Biosciences), and analysis of flow cytometry data was performed using FlowJo Software (Treestar). FACS-sorted mG-positive and mT-positive cancer cells were separately injected into NSG mice as described above. For the transplantation of mixed cells, FACS-sorted mG-positive and mT-positive cancer cells were mixed in 100 µl HBSS containing 30% Matrigel (BD Bioscience). The mixed cell suspension was injected into NSG mice as described above. For the orthotopic model, mG/EpCAM-and mT/EpCAM-positive cells were FACS-sorted and injected submucosally into the anterior aspect of the bladder dome. Abdominal incisions were then closed with 4-0 Vicryl suture, and the surgical site was treated once with topical antibiotic ointment. Shh CreER ; R26 mTmG mice (five different animals, bladder #1-5) injected with TM on three consecutive days were exposed to BBN for 6 months and bladder tumors analyzed (H&E, left panels; mG/mT expression, right panels). L, bladder lumen. Representative images are shown in Figure 2 . Figure 4 Ablation of Shh-expressing basal cells renders bladder resistant to nitrosamine-induced formation of invasive carcinoma. TM was injected into Shh CreER ; R26 DTA mice (twelve different animals; bladder #1-6, with TM; bladder #7-12, without TM) on five consecutive days to ablate Shh-expressing basal cells, and these mice subsequently were exposed to BBN for 6 months (right panels; without TM) and 8 months (left panels; with TM). Bladder tissues were analyzed by H&E staining. L, bladder lumen. Representative images are shown in Figure 3c . Scale bars represent 50μm. Supplementary Figure 5 Tumor-propagating cells derive exclusively from Shh-positive cells in the CIS lesion. (a) Shh CreER ; R26 mTmG mice (four different animals: Bladder #1-4) were exposed to BBN for 4 months to induce development of CIS. TM was injected on three consecutive days to label Shhexpressing CIS cells prior to sacrifice and analysis of bladder tissues by H&E staining (left panel) or by immunostaining for mG and CK5 (green and red, respectively, in three right panels). L, bladder lumen. (b) mG/EpCAM-positive and mT/EpCAM-positive populations from six different invasive carcinomas generated as described in Fig. 5b were separated using FACS. (c) BBNinduced bladder tumor cells were injected intramurally into the dome of the bladder. (d) Orthotopic transplantation with serial dilutions of mG/EpCAMpositive and mT/EpCAM-positive cells from invasive carcinomas #2 and #3 (invasive carcinoma # 1 is shown in Fig. 5e ). Representative images for (a) and (d) are shown in Figure 5a , and 5e, respectively. Scale bars represent 50μm.
